GlobalGov › Germany › Pharmaceuticals › Solicitation

Germany – Pharmaceutical products – Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V) for medicinal products containing the active ingredient filgrastim (ATC code: L03AA02).

Original title (German): Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Filgrastim (ATC-Code: L03AA02).

Health · Germany government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

September 27, 2026
Response Due
Active
Status

Opportunity Overview

Germany – Pharmaceutical products – Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V) for medicinal products containing the active ingredient filgrastim (ATC code: L03AA02).

This Germany Pharmaceuticals opportunity is one most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyHealth
CountryGermany
CategoryPharmaceuticals
PublishedOctober 07, 2024
Procurement stageActive solicitation
Response dueSeptember 27, 2026
StatusOpen — accepting responses
Original languageGerman — members read it in their own language
Official sourceView original notice
Last verifiedSeptember 18, 2026

Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.

Germany market overview →Pharmaceuticals tenders in Germany →Browse all categories →

Related Opportunities in Germany

Germany – Pharmaceutical products – Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V) for the active ingredient oxybutynin (exclusively FER/IST), ATC G04BD04 for the period 01.04.2025 - 31.03.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Carglumsäure, ATC A16AA05 für die Zeit 01.07.2025 - 30.06.2027 (zzgl. Verlängerungsoption 1x12 Monate)
Germany – Pharmaceutical products – Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V) for the active ingredient dolutegravir + rilpivirine, ATC J05AR21, for the period 01.07.2025 - 30.06.2027
Germany – Pharmaceutical products – Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V) for the active ingredient rilpivirine, ATC J05AG05, for the period 01.07.2025 - 30.06.2027
Germany – Pharmaceutical products – Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V) for the active ingredient Elafibranor (OBO), ATC A05AX06 for the period 01.12.2024 - 30.11.2026
Germany – Pharmaceutical products – Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V) for the active ingredient raltegravir, ATC J05AJ01, for the period 01.11.2025 - 31.10.2027
Germany – Pharmaceutical products
Germany – Pharmaceutical products

See every Germany Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free Germany Pharmaceuticals intelligence report in your inbox

A personalized report on Germany Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.